Yahoo · Oct 6, 2026
INSM Stock Slides on CFO Exit, Reiterates '26 Sales View
Insmed shares slide after CFO Sara Bonstein's surprise exit, though the company reaffirms 2026 revenue guidance for Brinsupri and Arikayce.
AC
NASDAQ · ACIU
AC Immune S.A.
Healthcare · Biotechnology
$2.09
Up+$0.18 (+8.61%)
Updated Nov 4, 2026, 8:19 PM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 294.76M
- P/E ratio
- -3.11
- Dividend yield
- 0.00%
- 52-week range
- $2.02 – $3.49
- Volume
- 134.8K
- Avg. volume
- 714.24K
Price performance · ACIU
ACIU price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
ACIU closed at $2.09 after 21 trading sessions, down 17.06% for the selected period.
- Last close
- $2.09
- Period change
- -17.06%
- Period low
- $2.06
- Period high
- $2.57
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $2.06 | $2.16 | $2.06 | $2.09 | 134.8K |
| Nov 2, 2026 | $2.23 | $2.32 | $2.015 | $2.06 | 470.83K |
| Oct 30, 2026 | $2.37 | $2.37 | $2.21 | $2.22 | 105.1K |
| Oct 29, 2026 | $2.34 | $2.43 | $2.32 | $2.37 | 105.22K |
| Oct 28, 2026 | $2.21 | $2.39 | $2.19 | $2.37 | 227.12K |
| Oct 27, 2026 | $2.31 | $2.36 | $2.03 | $2.25 | 469.03K |
| Oct 26, 2026 | $2.41 | $2.42 | $2.29 | $2.31 | 397.92K |
| Oct 23, 2026 | $2.46 | $2.48 | $2.40 | $2.42 | 139.55K |
| Oct 22, 2026 | $2.45 | $2.52 | $2.45 | $2.50 | 73.03K |
| Oct 21, 2026 | $2.46 | $2.52 | $2.46 | $2.47 | 89.04K |
| Oct 20, 2026 | $2.41 | $2.525 | $2.395 | $2.49 | 140.1K |
| Oct 19, 2026 | $2.38 | $2.44 | $2.37 | $2.435 | 88.82K |
| Oct 16, 2026 | $2.45 | $2.47 | $2.38 | $2.39 | 126.85K |
| Oct 15, 2026 | $2.43 | $2.46 | $2.3805 | $2.45 | 86.89K |
| Oct 14, 2026 | $2.37 | $2.41 | $2.35 | $2.40 | 209.78K |
| Oct 13, 2026 | $2.43 | $2.44 | $2.39 | $2.40 | 194.92K |
| Oct 12, 2026 | $2.50 | $2.50 | $2.42 | $2.45 | 148.47K |
| Oct 9, 2026 | $2.55 | $2.59 | $2.475 | $2.50 | 271.33K |
| Oct 8, 2026 | $2.57 | $2.61 | $2.50 | $2.55 | 231.86K |
| Oct 7, 2026 | $2.52 | $2.59 | $2.50 | $2.57 | 125.08K |
| Oct 6, 2026 | $2.72 | $2.72 | $2.51 | $2.52 | 277.84K |
Latest ACIU news
The latest Smart Investors Daily articles mentioning ACIU.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ACIU research
Overview
Company profile and research snapshot.
Company profile
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $9.00
- Implied upside
- —
- Analysts
- 9
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 23, 2026 | BTIG | Buy | — |
| Aug 20, 2026 | BTIG | Buy | — |
| Aug 5, 2026 | BTIG | Buy | — |
| May 4, 2026 | BTIG | Buy | — |
| Mar 16, 2026 | BTIG | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 6, 2026
PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal
Pacira expands Exparel's European reach through Molteni, adding new markets and revenue streams, with the first commercial sale in Europe expected in 2027.
Yahoo · Oct 5, 2026
Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation
RARE's gene therapy for Sanfilippo syndrome wins EMA validation, advancing the treatment toward formal review in Europe.
Yahoo · Oct 5, 2026
Novo's Denecimig BLA Review Delayed by FDA Facility Remediation Work
NVO's denecimig FDA review is delayed by manufacturing facility remediation, while no clinical efficacy or safety deficiencies were identified.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
